Skip to main content
Top
Published in: Investigational New Drugs 3/2019

01-06-2019 | PRECLINICAL STUDIES

Induction of endoplasmic reticulum stress by aminosteroid derivative RM-581 leads to tumor regression in PANC-1 xenograft model

Authors: Martin Perreault, René Maltais, Jenny Roy, Sylvain Picard, Ion Popa, Nicolas Bertrand, Donald Poirier

Published in: Investigational New Drugs | Issue 3/2019

Login to get access

Summary

The high fatality and morbidity of pancreatic cancer have remained almost unchanged over the last decades and new clinical therapeutic tools are urgently needed. We determined the cytotoxic activity of aminosteroid derivatives RM-133 (androstane) and RM-581 (estrane) in three human pancreatic cancer cell lines (BxPC3, Hs766T and PANC-1). In PANC-1, a similar level of antiproliferative activity was observed for RM-581 and RM-133 (IC50 = 3.9 and 4.3 μM, respectively), but RM-581 provided a higher selectivity index (SI = 12.8) for cancer cells over normal pancreatic cells than RM-133 (SI = 2.8). We also confirmed that RM-581 induces the same ER stress-apoptosis markers (BIP, CHOP and HERP) than RM-133 in PANC-1 cells, pointing out to a similar mechanism of action. Finally, these relevant in vitro results have been successfully translated in vivo by testing RM-581 using different doses (10–60 mg/kg/day) and modes of administration in PANC-1 xenograft models, which have led to tumor regression without any sign of toxicity in mice (animal weight, behavior and histology). Interestingly, RM-581 fully reduced the pancreatic tumor growth when administered orally in mice.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cancer Facts & Figures 2017 - American Cancer Society. (2017) Cancer Facts & Figures 2017 - American Cancer Society. (2017)
21.
go back to reference Perreault M, Maltais R, Kenmogne LC, Létourneau D, Gobeil S, LeHoux JG, Poirier D (2018) Implication of STARD5 and cholesterol homeostasis disturbance in the endoplasmic reticulum stress-related response induced by pro-apoptotic aminosteroid RM-133. Pharmacol Res 128:52–60CrossRefPubMed Perreault M, Maltais R, Kenmogne LC, Létourneau D, Gobeil S, LeHoux JG, Poirier D (2018) Implication of STARD5 and cholesterol homeostasis disturbance in the endoplasmic reticulum stress-related response induced by pro-apoptotic aminosteroid RM-133. Pharmacol Res 128:52–60CrossRefPubMed
25.
go back to reference Dutour R, Maltais R, Perreault M, Roy J, Poirier D (2018) Parallel solid-phase synthesis using a new diethylsilylacetylenic linker and leading to mestranol derivatives with potent antiproliferative activities on multiple cancer cell lines. Anti Cancer Agents Med Chem (in press) Dutour R, Maltais R, Perreault M, Roy J, Poirier D (2018) Parallel solid-phase synthesis using a new diethylsilylacetylenic linker and leading to mestranol derivatives with potent antiproliferative activities on multiple cancer cell lines. Anti Cancer Agents Med Chem (in press)
26.
40.
42.
go back to reference Fryer RA, Barlett B, Galustian C, Dalgleish AG (2011) Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD lenalidomide. Anticancer Res 31:3747–3756PubMed Fryer RA, Barlett B, Galustian C, Dalgleish AG (2011) Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD lenalidomide. Anticancer Res 31:3747–3756PubMed
Metadata
Title
Induction of endoplasmic reticulum stress by aminosteroid derivative RM-581 leads to tumor regression in PANC-1 xenograft model
Authors
Martin Perreault
René Maltais
Jenny Roy
Sylvain Picard
Ion Popa
Nicolas Bertrand
Donald Poirier
Publication date
01-06-2019
Publisher
Springer US
Published in
Investigational New Drugs / Issue 3/2019
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-018-0643-4

Other articles of this Issue 3/2019

Investigational New Drugs 3/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine